HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors TAIPEI, SHANGHAI, AND SAN FRANCISCO, Dec. 11, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that new clinical data from its flagship macrophage-checkpoint program,...
MATELASER W1 REGEN: The Lightest 24g and Highest 5,100 mW/cm² Wearable Red Light Therapy Device Debuts on Kickstarter
MIAMI, Dec. 11, 2025 /PRNewswire/ -- MATELASER, INC., a pioneer in mobile laser therapy, today announced the official launch of its global crowdfunding campaign for the W1 REGEN, a breakthrough device that brings clinic-grade laser therapy into an ultra-miniature 24g wearable form. Priced at just $99, W1 REGEN officially breaks the cost barrier for true medical-grade photobiomodulation, marking a major step forward in the...
The 2nd International Cerebro-cardiovascular Medical Innovation Summit (ICMIS 2025) Opens in Hong Kong: AI Technology and Digital Health Usher in a New Chapter of Translational Medicine.
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Cerebro-cardiovascular conditions have continued to pose a public health burden. The convergence of population ageing and lifestyle risk factors has made "earlier detection, earlier intervention, and accessible and affordable prevention and management" a common challenge for global healthcare systems. Concurrently, the rapid development of technologies such as Artificial Intelligence (AI), digital health...
Life-Space Fiber Jelly: The Fiber Fix Modern Guts Have Been Waiting For
The smarter, tastier way to meet your daily fiber needs, powered by Litesse for smooth digestion and real gut results. KUALA LUMPUR, Malaysia, Dec. 11, 2025 /PRNewswire/ -- In a world where convenience often outweighs nutrition, Life-Space Fiber Jelly steps in the jelly way to gut health and lightness. The interactive showcase held in Kuala Lumpur, invited attendees to...
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistance The study achieved its objective, as the new Q6W extended dosing interval produced encouraging anti-tumor efficacy and immunological...
OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases
Collaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets in metabolic diseases OTR Therapeutics will receive an initial upfront payment of USD 20 million, which may increase to USD 30 million under certain pre-agreed conditions,...
Rhinocare Korea Accelerates Global Expansion with Singapore Joint Venture
K-Healthtech Firm Targets Rapid Global Scale-Up with Drug-Free Nasal-Care Innovation SINGAPORE and SEOUL, South Korea, Dec. 11, 2025 /PRNewswire/ -- Rhinocare Korea, a medtech innovator specializing in drug-free respiratory care, announced plans to establish a joint venture (JV) in Singapore as part of its strategy to expand across Asia-Pacific, Europe, and North America. The move follows strong global interest in...
Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody) combined with chemotherapy as a first-line treatment for locally advanced unresectable or metastatic triple-negative breast cancer (TNBC) at the 2025 European Society for...
Hakka Medicine: From Millennia of Heritage to Modern Industrialization – A Health Path Connecting the World
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Hakka medicine is the result of deep integration between traditional Central Plains Chinese medicine and the natural environment of southern China, carrying profound historical heritage and unique clinical value. The Seventh World Hakka Entrepreneurs Convention was held in Meizhou, Guangdong from November 23 to 25. With the theme of "Gather Global Hakka Entrepreneurs •...
Samsung Biologics recognized as a global leader in water security
Company receives the highest Water Security rating in two years into participation Recognized for exceptional leadership in environmental stewardship INCHEON, South Korea, Dec. 11, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that it has received from the Carbon Disclosure Project (CDP)...
